---
title: "Roche Holding (ROG) stock news, pipeline, cash and catalysts"
url: "https://aibio.space/companies/roche/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Roche Holding news for investors: Roche is a Swiss healthcare group that sells cancer, neurology, eye and immune medicines and runs a large diagnostics…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Roche faces a run of FDA decisions while older drugs fade

Roche has a large revenue base and an unusually dense run of FDA dates between late November and February. The pipeline is deep, but growth depends on new launches outpacing the decline of older drugs. Currency and China pricing add noise.

Read the full desk view

aibio.space Investor Rank · Opinion

**9** /10 Most positive view

A large, broad portfolio with sales up 6% and a dense run of FDA dates, while growth depends on launches outpacing older drugs in decline.

- **Technology**: 2/2

- **Odds**: 2/2

- **Balance sheet**: 2/2

- **Risk**: 1/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Broad and proven.** Roche sells in oncology, neurology, eye disease and diagnostics, and its late-stage list now includes an oral SERD, a KRAS G12C inhibitor, a BTK inhibitor and an incretin.

- **Odds**: **Favorable near term.** Several FDA decisions fall between Nov 30, 2026 and Feb 9, 2027, and most assets are at filing stage, where 90.6% of applications historically win approval.

- **Balance sheet**: **Strong but levered.** Net debt was CHF 22.1 billion at June 30 after dividends, against CHF 4.2 billion of first-half free cash flow.

- **Main risk**: **Replacement pace.** Perjeta, Kadcyla, Actemra and Herceptin are shrinking, and five products make up about 46% of pharma sales.

- **Watch next**: **FDA on giredestrant.** The early-stage decision is due Nov 30, 2026 and the advanced-disease decision Dec 18, 2026.

## Top news on Roche

## Dates

**Nov 30, 2026**
FDA decision on giredestrant in early-stage ER-positive breast cancer [Source](https://www.roche.com/media/releases/med-cor-2026-06-02)

**November 2026**
FDA decision on Gazyva in primary membranous nephropathy [Source](https://www.roche.com/media/releases/med-cor-2026-07-15)

**Dec 18, 2026**
FDA decision on giredestrant plus everolimus in advanced breast cancer [Source](https://www.roche.com/media/releases/med-cor-2026-10-22)

**Feb 9, 2027**
FDA decision on Lunsumio VELO plus Polivy in large B-cell lymphoma [Source](https://www.roche.com/media/releases/med-cor-2026-06-18)

## The money

Net debt of CHF 22.1 billion at June 30, 2026 (CHF 16.2 billion at Dec 31, 2025) after CHF 8.3 billion of dividends; first-half free cash flow CHF 4.2 billion. No runway guidance; the company is profitable. [Source](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf)

Nine-month 2026 group sales CHF 46.5 billion, up 6% at constant exchange rates and 1% in CHF; third-quarter sales grew 7% at constant rates. [Source](https://www.roche.com/media/releases/med-cor-2026-10-22)

## Risks on the record

- Swiss franc strength: nine-month sales grew 6% at constant rates but 1% in francs. [Source](https://www.roche.com/media/releases/med-cor-2026-10-22)
- Older products are shrinking: Perjeta, Kadcyla, Actemra and Herceptin all fell in the nine months, and China diagnostics pricing reforms weigh on Asia-Pacific. [Source](https://www.roche.com/media/releases/med-cor-2026-10-22)
- Net debt rose to CHF 22.1 billion at June 30 from CHF 16.2 billion at year-end, after dividends. [Source](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf)

## Questions investors ask

### What is aibio.space's Investor Rank for Roche Holding?

9 out of 10, our most positive view. A large, broad portfolio with sales up 6% and a dense run of FDA dates, while growth depends on launches outpacing older drugs in decline. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### When will the FDA decide on Roche's giredestrant?

The FDA set a decision date of November 30, 2026 for giredestrant in early-stage ER-positive breast cancer, under Priority Review. For advanced disease with everolimus, Roche says the date is December 18, 2026. [Source](https://www.roche.com/media/releases/med-cor-2026-10-22)

### How much did Roche's sales grow in the third quarter of 2026?

Roche said third-quarter sales grew 7% at constant exchange rates and 8% in Swiss francs. For the first nine months, sales were CHF 46.5 billion, up 6% at constant rates and 1% in francs. [Source](https://www.roche.com/media/releases/med-cor-2026-10-22)

### How much debt does Roche have?

Roche reported net debt of CHF 22.1 billion at June 30, 2026, up from CHF 16.2 billion at the end of 2025. The report said the rise reflected CHF 8.3 billion of dividends, partly offset by CHF 4.2 billion of free cash flow. [Source](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf)

### Did Roche's divarasib beat sotorasib and adagrasib in phase III?

Roche said the Krascendo 1 trial met its progression-free survival endpoint and showed a statistically significant overall survival result at interim analysis versus sotorasib or adagrasib. The company has not yet published the numbers. [Source](https://www.roche.com/media/releases/med-cor-2026-07-02)

### Does Roche have an obesity drug?

Roche's enicepatide, a once-weekly GLP-1/GIP agonist, is in two phase III weight management studies. In a phase II diabetes trial it cut HbA1c by 2.65% and weight by 15.5% at 48 weeks at the 24 mg dose. [Source](https://www.roche.com/media/releases/med-cor-2026-09-22)

## Legal and investor matters

Checked against Roche Holding filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

The legal cases note (Note 20) of the 2025 Finance Report and the legal section of the 2026 Half-Year Report list competition, patent, product-liability and Anti-Terrorism Act matters. Neither mentions a securities class action or shareholder derivative suit. [Source](https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf)

1. 2026-07-23 Regulatory Italian competition authority issues Statement of Objections to Genentech over alleged biosimilar delay Roche's half-year report states that on 2026-04-30 the Italian Competition Authority issued a Statement of Objections against Genentech and other companies, alleging anti-competitive practices aimed at delaying a biosimilar's entry into the Italian market. Genentech filed its response on 2026-07-17, and a hearing was planned for 2026-07-28. The group says it is vigorously defending itself and that the outcome cannot be determined at this time. Status: pending [Roche Half-Year Report 2026 (published 2026-07-23)](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf)
2. 2026-07-23 Litigation Appeals court reaffirms 2022 ruling in Iraq Anti-Terrorism Act suit against Roche units The half-year report says that on 2026-01-23 the US Court of Appeals for the District of Columbia Circuit reaffirmed its prior 2022 decision and remanded the Iraqi Ministry of Health case for further proceedings. The complaint, filed on behalf of US service members and their relatives, alleges the defendants violated the US Anti-Terrorism Act by funding terrorist organisations through their sales practices. En banc review was denied on 2026-04-23, and the defendants are considering a petition for certiorari to the US Supreme Court. US Court of Appeals for the District of Columbia Circuit · Status: pending [Roche Half-Year Report 2026 (published 2026-07-23)](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf)
3. 2026-07-23 Other Roche books CHF 765 million of global restructuring costs in first half of 2026 Roche reports that it continued implementing global restructuring plans in the first half of 2026, with total costs of CHF 765 million against CHF 1,023 million a year earlier. The Pharmaceuticals Division incurred CHF 346 million, primarily for research and development optimisation and a business process transformation. The Diagnostics Division incurred CHF 239 million, and corporate costs were CHF 180 million. [Roche Half-Year Report 2026 (published 2026-07-23)](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf)
4. 2026-03-10 Governance Roche shareholders approve exchange of Genussscheine for participation certificates On 2026-03-10 the Annual General Meeting of Roche shareholders approved changes to the group's capital structure. Non-voting equity securities (Genussscheine) were exchanged for participation certificates with a nominal value of CHF 0.001, and the bearer shares' nominal value was cut from CHF 1.00 to CHF 0.001. Bearer shareholders received CHF 0.999 per share, totalling CHF 106,584,309. The certificates were listed on SIX Swiss Exchange on 2026-03-17. [Roche Half-Year Report 2026 (published 2026-07-23)](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf)
5. 2026-01-29 Litigation Herceptin multidose vial MDL: class certification ruling still pending Roche's 2025 finance report states that Genentech faces multidistrict litigation in the Northern District of Oklahoma brought by cancer centres. The master complaint alleges Herceptin multidose vials sold between 1998 and 2017 were underfilled. Plaintiffs moved for class certification on 2024-09-27, a hearing took place on 2025-01-30, and the parties continue to await the ruling. Roche says the outcome cannot be determined. US District Court for the Northern District of Oklahoma (MDL) · Status: pending [Roche Finance Report 2025 (published 2026-01-29)](https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf)
6. 2026-01-29 Regulatory Belgian competition authority issues Statement of Objections to Roche over alleged biosimilar delay Roche's 2025 finance report states that on 2025-03-17 the Belgian Competition Authority issued a Statement of Objections against Roche SA and Roche Holding Ltd. It concerns a strategy aimed at delaying the entry of biosimilars of two anticancer medicines into Belgium between 2017 and 2020. The Auditor's Office sent a proposed decision on 2025-11-28. Roche says it is vigorously defending itself and the outcome cannot be determined. Status: pending [Roche Finance Report 2025 (published 2026-01-29)](https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf)
7. 2026-01-29 Regulatory French fine over Avastin and Lucentis paid again after Supreme Court ruling In 2020 the French Competition Authority found that Roche, Genentech and Novartis had infringed competition law on Avastin and Lucentis and fined Roche and Genentech EUR 60 million. After the Paris Court of Appeal ruled for Roche in 2023, the French Supreme Court overturned that ruling on 2025-06-25 for insufficient reasoning. Roche and Genentech filed another appeal on 2025-07-29, and the fine was again paid under protest in December 2025. The report also describes a related Turkish Competition Authority matter. Paris Court of Appeal · Status: appealed [Roche Finance Report 2025 (published 2026-01-29)](https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf)
8. 2026-01-29 Regulatory South African regulator pursues excessive-pricing referral over Herceptin Roche's 2025 finance report states that on 2022-02-08 the South African Competition Commission filed a referral with the Competition Tribunal against Roche Holding, F. Hoffmann-La Roche and Roche Products for alleged excessive pricing of Herceptin. The alleged pricing took place between January 2011 and November 2020 in the private sector. The Commission asks the Tribunal to impose a penalty. Roche says it is vigorously defending itself. Status: pending [Roche Finance Report 2025 (published 2026-01-29)](https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf)
9. 2025-03-06 Litigation Genentech settles University of Pennsylvania Herceptin patent case The University of Pennsylvania sued Genentech on 2022-01-31, claiming Herceptin, Perjeta, Phesgo and Herceptin Hylecta infringed its US Patent No. 7,625,558. After a tentative summary judgment ruling in January 2025 that held 13 claims invalid, the parties signed a settlement agreement on 2025-03-06. The university filed a notice of dismissal on 2025-03-13, and Roche reports that the matter is now concluded. Status: settled [Roche Finance Report 2025 (published 2026-01-29)](https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Giredestrant | Early-stage ER-positive breast cancer (adjuvant) | FDA Priority Review, decision date Nov 30, 2026 [Source](https://www.roche.com/media/releases/med-cor-2026-06-02) |
| Fenebrutinib | Relapsing and primary progressive multiple sclerosis | FDA filings accepted with Priority Review [Source](https://www.roche.com/media/releases/med-cor-2026-10-22) |
| Divarasib | Previously treated KRAS G12C non-small cell lung cancer | Phase III Krascendo 1 positive; two more phase III trials ongoing [Source](https://www.roche.com/media/releases/med-cor-2026-07-02) |
| Gazyva (obinutuzumab) | Primary membranous nephropathy | FDA Priority Review, decision expected by November 2026 [Source](https://www.roche.com/media/releases/med-cor-2026-07-15) |
| Lunsumio VELO plus Polivy | Relapsed or refractory large B-cell lymphoma | sBLA accepted, decision by Feb 9, 2027 [Source](https://www.roche.com/media/releases/med-cor-2026-06-18) |
| Enicepatide (CT-388) | Obesity; type 2 diabetes | Phase III in weight management; phase II diabetes data Sept 2026 [Source](https://www.roche.com/media/releases/med-cor-2026-09-22) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Roche's trial releases use strong wording, and the records qualify it in four of the releases reviewed

Roche's half-year report and sales release are consistent with each other, and the company shows its currency drag openly. The gaps are in how the trial releases are worded: fenebrutinib's disability claim has a confidence interval that crosses 1, enicepatide's primary endpoint timepoint differs from its registry entry, giredestrant's "first significant advance" wording rests on an open-label trial with immature survival data, and divarasib is predicted to be a new standard of care without a single effect size. No securities litigation is disclosed.

1. Press release vs filing · weight medium Five new late-stage medicines in the release, CHF 1.0 billion of stopped compounds in the report **The company said:** "We advanced another five potential new medicines into the final stage of development this year and now aim to bring up to 20 new medicines to patients by 2030." [source](https://www.roche.com/media/releases/med-cor-2026-10-22) **The record says:** The half-year report says "The Pharmaceuticals Division recorded impairment charges to intangible assets of CHF 1.0 billion due to decisions to stop the development of the respective compounds," including CHF 0.4 billion for selnoflast, CHF 0.2 billion for acmopatide (CT-868) and CHF 0.2 billion for a PD-1-regulated IL-2 programme. It also says IFRS diluted EPS fell 8% in Swiss francs "due to the additional effects of the appreciation of the Swiss franc and intangible asset impairment", and rose 5% at constant exchange rates. [source](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf) **Our view:** The sales release is about sales and does not mention terminated programs, so this is a gap in emphasis, not a contradiction. The half-year report says the stopped compounds were acquired in the Inflazome, Carmot and Good Therapeutics deals.
2. Science · weight high Fenebrutinib: "slow disability" rests on a non-inferiority result **The company said:** "Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus." [source](https://www.roche.com/media/releases/med-cor-2026-10-22) **The record says:** Roche's Sept. 30 release says FENtrepid "met its primary endpoint of non-inferiority compared with Ocrevus" and that fenebrutinib "numerically reduced the risk of progression by 12%" (hazard ratio 0.88, 95% confidence interval 0.75, 1.03). It adds that liver enzyme elevations were "observed more often with fenebrutinib compared to Ocrevus in the PPMS study" and that "an imbalance in reported fatalities was observed across the three pivotal studies", and that "the deaths occurred at different timepoints and had various causes". ClinicalTrials.gov lists 985 participants and a primary outcome of time to onset of composite 12-week confirmed disability progression. [source](https://clinicaltrials.gov/study/NCT04544449) **Our view:** The sales release uses the word "numerical", which is accurate, but the interval includes no effect, so the trial shows fenebrutinib is not worse than Ocrevus rather than better. The liver and fatality language sits in the standalone release and not in the sales summary, and it is part of the safety picture the standalone release describes.
3. Science · weight medium Giredestrant: 30% relative cut is 2.8 points at three years, in an open-label trial **The company said:** "Giredestrant represents the first significant advance in adjuvant endocrine therapy in over 20 years" [source](https://www.roche.com/media/releases/med-cor-2026-06-02) **The record says:** The same release gives the effect as "92.4% of patients in the giredestrant arm were alive and free of invasive disease versus 89.6% in the SoC ET arm" at three years and says "Overall survival (OS) data were immature at the time of this analysis, but a clear positive trend was observed." It also reports a treatment discontinuation rate of 5.3% for giredestrant versus 8.2% for standard of care endocrine therapy. It calls lidERA "a phase III, randomised, open-label, multicentre study". ClinicalTrials.gov lists 4,170 enrolled, a primary outcome of invasive disease-free survival, and overall survival as a secondary outcome. [source](https://clinicaltrials.gov/study/NCT04961996) **Our view:** The hazard ratio of 0.70 is clear and the release shows the absolute figures, so it is transparent. Still, a 2.8 point gap at three years, immature survival data and no blinding make "first significant advance in adjuvant endocrine therapy in over 20 years" a strong phrase. The release also reports a clear positive survival trend and the lower discontinuation rate.
4. Science · weight medium Enicepatide: release says week 48 primary endpoints, registry lists week 36 **The company said:** "In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks." [source](https://www.roche.com/media/releases/med-cor-2026-09-22) **The record says:** The release states "The dual primary outcomes are changes from baseline in HbA1c and body weight at week 48." The ClinicalTrials.gov record, last updated Oct. 6, 2026, lists the primary outcomes as "Percent Change in Body Weight from Baseline to Week 36" and "Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36", with the week 48 versions listed as secondary outcomes. [source](https://clinicaltrials.gov/study/NCT06628362) **Our view:** This may be a protocol change not yet reflected in the registry, and we cannot tell from the record. The release does not say whether the primary timepoint was changed. The headline figures (2.65% HbA1c, 15.5% weight loss) are for the 24 mg arm and the release gives no placebo comparison for them.
5. Science · weight medium Divarasib is predicted to be a new standard of care before any effect size is public **The company said:** "These results should establish divarasib as a new standard of care for previously-treated lung cancer patients with this genetically defined tumor subtype." [source](https://www.roche.com/media/releases/med-cor-2026-07-02) **The record says:** The release describes Krascendo 1 as "randomised, open-label, multicentre" with 338 adults, says the primary endpoint is BICR-assessed progression-free survival with overall survival a secondary endpoint, and states "Statistical significance for overall survival was achieved at the interim analysis". It gives no hazard ratios or medians and says data will be presented at "an upcoming medical meeting". ClinicalTrials.gov lists progression-free survival as the sole primary outcome. [source](https://clinicaltrials.gov/study/NCT06497556) **Our view:** The release reports statistically significant PFS and OS results head to head against sotorasib or adagrasib. But "best-in-class" and "standard of care" language arrives without numbers, so the size of the benefit and the toxicity trade-off are unknown.
6. Legal and disclosure record · weight low No securities litigation or enforcement disclosed in the latest filing **The record says:** Note 10 of the half-year report lists legal provisions of CHF 166 million at June 30, 2026. It describes the Iraqi Ministry of Health case, where "the US Court of Appeals for the District of Columbia Circuit reaffirmed its prior decision dated 4 January 2022 and remanded the case for further proceedings" on Jan. 23, 2026; a petition for en banc review was denied on April 23, 2026 and the defendants are considering a petition to the US Supreme Court. The note also describes an Italian Competition Authority Statement of Objections issued April 30, 2026 against Genentech, Inc. and other companies, alleging anti-competitive practices aimed at delaying the entry of a biosimilar into the Italian market; Genentech responded on July 17, 2026 and a hearing was planned for July 28, 2026. Roche says of both that "The outcome of this matter cannot be determined at this time." Note 10 lists no securities class action. [source](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf) **Our view:** Both matters are unresolved, and Roche says it is vigorously defending itself and cannot determine the outcome at this time.

Documents we compared

- [Roche Half-Year Report 2026](https://assets.roche.com/f/176343/x/8a0b362d66/hy26e.pdf) 2026-07-21
- [Roche nine-month 2026 sales release](https://www.roche.com/media/releases/med-cor-2026-10-22) 2026-10-22
- [Roche fenebrutinib FDA filing acceptance release](https://www.roche.com/media/releases/med-cor-2026-09-30) 2026-09-30
- [Roche giredestrant FDA filing acceptance release](https://www.roche.com/media/releases/med-cor-2026-06-02) 2026-06-02
- [Roche enicepatide phase II diabetes release](https://www.roche.com/media/releases/med-cor-2026-09-22) 2026-09-22
- [Roche divarasib Krascendo 1 release](https://www.roche.com/media/releases/med-cor-2026-07-02) 2026-07-02
- [ClinicalTrials.gov NCT04544449 (FENtrepid)](https://clinicaltrials.gov/study/NCT04544449) 2026-09-17
- [ClinicalTrials.gov NCT04961996 (lidERA)](https://clinicaltrials.gov/study/NCT04961996) 2026-10-15
- [ClinicalTrials.gov NCT06628362 (enicepatide CT-388-104)](https://clinicaltrials.gov/study/NCT06628362) 2026-10-06
- [ClinicalTrials.gov NCT06497556 (Krascendo 1)](https://clinicaltrials.gov/study/NCT06497556) 2026-09-16

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open SIX:ROG on TradingView](https://www.tradingview.com/symbols/SIX-ROG/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/roche/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Roche Holding (ROG) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/roche/